主要文件

查看所有文档

Y0001101

干扰素β-1A

Name: 干扰素β-1A
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

化学文摘社编号:

145258-61-3

NACRES:

NA.24

UNSPSC Code:

41116107

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

interferon

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

shipped in

dry ice

storage temp.

−70°C

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Interferon β-1a EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

存储类别

10 - Combustible liquids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

常规特殊物品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity deﬁcits in multiple sclerosis.

Francesco Mori et al.

Functional neurology, 27(3), 163-168 (2013-02-14)

Acute inﬂammation is associated with cognitive deﬁcits and alterations of cortical plasticity in multiple sclerosis (MS). We tested whether early treatment with high-dose interferon (IFN) beta-1a, known to reduce inﬂammatory activity, improves cortical function and cognitive deﬁcits in MS. Eighty

Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity.

James G Barnard et al.

Journal of pharmaceutical sciences, 102(3), 915-928 (2012-12-13)

Interferon-β (IFN-β) products have been used for many years in the treatment of multiple sclerosis and include recombinant IFN-β-1b (Betaseron®) and IFN-β-1a (Avonex® and Rebif®). All three products lead to the formation of neutralizing antibodies (NAbs) and resulting loss of

Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.

Barry Singer et al.

BMC neurology, 12, 154-154 (2012-12-12)

In patients with relapsing-remitting multiple sclerosis (RRMS), subcutaneous (sc) interferon (IFN)β-1a and IFNβ-1b have been shown to reduce relapse rates. A formulation of IFNβ-1a has been produced without fetal bovine serum and without human serum albumin as an excipient (not

查看所有相关文献

全球贸易项目编号

货号	GTIN
Y0001101	04061833796993